BDRXBiodexa Pharmaceuticals Plc · NASDAQ (ADS) · $0.35 · $360.4K mkt cap
Assessed Oct 2, 2026 · EFFECT registration filing
Is the float you're seeing correct?
7.64M
Estimated float

ADS-equivalent reconstruction.

NO REPORTED FLOAT
—
Reported float

Data-service feed, fetched today. The number TradingView and most screeners show.

Trade off 7.64M shares; data services have no usable float for this ticker.

Dilution risk6/10ELEVATED
CONFIDENCE: MEDIUM

We put the float at 7.64M; data services have no usable number. 9 reverse splits can add another 66% of the float.

  • Warrant overhang with repricing mechanism. The 4,408,436 Series P warrants equal 58% of the float.

  • Recently registered free-trading shares not in data feeds. The 2,204,218 ADSs issued on 2026-09-15 are registered (333-297473) and unlegended.

  • Rapid share count growth. ADS-equivalent outstanding grew from 451,636 (2025-12-31) to about 7.64M (2026-09-15), about +1,592% in 9 months.

From today's float to the ceiling

shares
7.64M
Estimated float
tradeable today
+19 can sell now
7.64M
Effective supply
float plus what sells on notice
+5.06M if floors are cut and warrants exercise
12.70M
Fully diluted
ceiling

Where the shares come from

each subtotal is a rung on the ladder above

Tradeable today
7.64M
Can sell now
Warrants in the money
Exercisable at or below the current tape.
+19
Effective supply
7.64M
Above the current price
Warrants out of the money
Struck above the current tape; supply only if the stock rises.
+5.06M
Options and RSUs
Employee equity; vests and settles over time.
+626
Fully diluted
12.70M

Not counted anywhere: ATM and shelf capacity. Convertible share counts use stated conversion prices.

See the full breakdown

Red flags, financing counterparties, the deal timeline, and every SEC filing — free with an account.

Sign in to continue

The facts

Price
$0.35
Market cap
$360.4K
Shares outstanding
1.03M
Reported float
—
Avg volume
2.47M
Reverse splits
9 · latest 1:10,000 (ordinary; ADS ratio 500,000 to 50, no change for ADS holders) · Jul 30, 2026
Going concern
Yes · 0 quarters runway
Quarterly burn
—

Market data as of Oct 14, 2026

Key dates

  • Oct 30, 2026 · Target effectiveness of the Series P resale F-1 (45 days from closing)
  • Nov 29, 2026 · Outside target for effectiveness if the SEC reviews it (75 days)
  • Mar 15, 2027 · Series P cashless exercise available if no effective resale registration
  • Sep 15, 2031 · Series P warrants expire